Literature DB >> 17662079

The role of intermittent androgen deprivation in prostate cancer.

Laurent Boccon-Gibod1, Peter Hammerer, Stephan Madersbacher, Nicolas Mottet, Tommaso Prayer-Galetti, Ulf Tunn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17662079     DOI： 10.1111/j.1464-410X.2007.07053.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  15 in total

Review 1.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

2.  Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling.

Authors:  Yoshito Hirata; Kai Morino; Koichiro Akakura; Celestia S Higano; Kazuyuki Aihara
Journal:  Sci Rep       Date:  2018-02-08       Impact factor: 4.379

3.  TCR-dependent transformation of mature memory phenotype T cells in mice.

Authors:  Xi Wang; Miriam B F Werneck; Boris G Wilson; Hye-Jung Kim; Michael J Kluk; Christopher S Thom; Jonathan W Wischhusen; Julia A Evans; Jonathan L Jesneck; Phuong Nguyen; Courtney G Sansam; Harvey Cantor; Charles W M Roberts
Journal:  J Clin Invest       Date:  2011-09-19       Impact factor: 14.808

Review 4.  Prostate cancer in senior adults: over- or undertreated?

Authors:  Ingrid Berger; Franz Böhmer; Anton Ponholzer; Stephan Madersbacher
Journal:  Wien Med Wochenschr       Date:  2009

5.  [Prostate-specific antigen for treatment monitoring].

Authors:  M Graefen; M Fröhner; M Wirth
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

Review 6.  Targeting anoikis resistance in prostate cancer metastasis.

Authors:  Shinichi Sakamoto; Natasha Kyprianou
Journal:  Mol Aspects Med       Date:  2010-02-11

7.  Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.

Authors:  Meng-Lei Zhu; Natasha Kyprianou
Journal:  FASEB J       Date:  2009-11-09       Impact factor: 5.191

8.  Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model.

Authors:  Yujuan Wang; Shubham Gupta; Vi Hua; Raquel Ramos-Garcia; Daniel Shevrin; Borko D Jovanovic; Joel B Nelson; Zhou Wang
Journal:  Prostate       Date:  2010-02-01       Impact factor: 4.104

Review 9.  Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.

Authors:  Hendrik Isbarn; Laurent Boccon-Gibod; Peter R Carroll; Francesco Montorsi; Claude Schulman; Matthew R Smith; Cora N Sternberg; Urs E Studer
Journal:  Eur Urol       Date:  2008-10-14       Impact factor: 20.096

10.  A triad of telomerase, androgen receptor and early growth response 1 in prostate cancer cells.

Authors:  Sheeba Jacob; Sumeet Nayak; Ruchi Kakar; Uddhav K Chaudhari; Dolly Joshi; Babu R Vundinti; Gwendolyn Fernandes; Ram S Barai; Sanjeeva D Kholkute; Geetanjali Sachdeva
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.